Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment

CompletedOBSERVATIONAL

Enrollment

50,075

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions

Neural Tube DefectsCongenital AbnormalitiesTeratogens

Trial Locations (5)

Good Shepherd Hospital, Lubombo

Hlathikhulu Hospital, Shiselweni

Mankayane Government Hospital, Manzini

Raleigh Fitkin Memorial Hospital, Manzini

Mbabane Government Hospital, Mbabane

All Listed Sponsors

collaborator

Ministry of Health Eswatini

UNKNOWN

collaborator

George Washington University

OTHER

lead

Elizabeth Glaser Pediatric AIDS Foundation

OTHER

NCT05883761 - Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment | Biotech Hunter | Biotech Hunter